comparemela.com

Latest Breaking News On - Taylorb young - Page 1 : comparemela.com

Promontory Therapeutics to Present Research on the Immunological Effects of PT-112 in Cancer Cell Mitochondria at SITC 2022

NEW YORK, Nov. 7, 2022 /PRNewswire/ Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherap.

United statesStephanie carringtonTakahiro yamazakiAlexis feinbergTaylorb youngLorenzo galluzziPromontory therapeutics incPrnewswire promontory therapeutics incMerck kgaMerck kgaaVirtual congressStrategic developmentTherapeutics incAnnual meetingPresentation sessionsPromontory therapeutic

Promontory Therapeutics Reports PT-112 s Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium

/PRNewswire/ Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, reported today new.

United statesBaja californiaComunidad autonoma de catalunaMatthew priceMark corbaeStephanie carringtonAlberto anelTaylorb youngPromontory therapeutics incNational cancer instituteHealth research instituteDepartment of biochemistryPrnewswire promontory therapeutics incAmerican association for cancer researchMerck kgaProfessor at university of zaragoza arag

Promontory Therapeutics to Present Research on PT-112 in Prostate Cancer at the 34th EORTC-NCI-AACR Symposium

/PRNewswire/ Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced.

United statesBaja californiaComunidad autonoma de catalunaRuth soler agestaMark corbaeStephanie carringtonTaylorb youngPromontory therapeutics incNational cancer instituteUniversity of zaragozaPrnewswire promontory therapeutics incAmerican association for cancer researchMerck kgaMerck kgaaVirtual congressStrategic development

Promontory Therapeutics Announces Peer-Reviewed Publication in Cancers of Selective Effects of PT-112 in Cancer Cell Models Driven by Mitochondrial Dysfunction

/PRNewswire/ Promontory Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, announced today the peer-reviewed.

United statesMatthew priceMark corbaeStephanie carringtonTaylorb youngMerck kgaPromontory therapeutics incMerck kgaaVirtual congressStrategic developmentDevelopmental therapeuticsOrphan drugPromontory therapeuticsPromontory therapeutics inc

Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesRegion flamandeJohan baeckRobert fallonMark corbaeStephanie carringtonJosephf odonnellTaylorb youngPromontory therapeutics incGlobal head of medical affairsPrnewswire promontory therapeutics incMerck kgaMerck kgaaAbbott laboratoriesStrategic developmentClinical development

vimarsana © 2020. All Rights Reserved.